JP7278595B2 - Ｃｄ３２１マーカーの発現に基づく循環腫瘍細胞の検出、定量化、及び／又は単離 - Google Patents

Ｃｄ３２１マーカーの発現に基づく循環腫瘍細胞の検出、定量化、及び／又は単離 Download PDF

Info

Publication number
JP7278595B2
JP7278595B2 JP2019551363A JP2019551363A JP7278595B2 JP 7278595 B2 JP7278595 B2 JP 7278595B2 JP 2019551363 A JP2019551363 A JP 2019551363A JP 2019551363 A JP2019551363 A JP 2019551363A JP 7278595 B2 JP7278595 B2 JP 7278595B2
Authority
JP
Japan
Prior art keywords
cells
subject
marker
tumor
ctcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512549A5 (https=
JP2020512549A (ja
Inventor
ブランパン，セドリック
ソティロポウロウ，パナギオタ
パシュシェンコ，エヴゲーニア
Original Assignee
ユニベルシテ リブレ デ ブリュッセル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシテ リブレ デ ブリュッセル filed Critical ユニベルシテ リブレ デ ブリュッセル
Publication of JP2020512549A publication Critical patent/JP2020512549A/ja
Publication of JP2020512549A5 publication Critical patent/JP2020512549A5/ja
Application granted granted Critical
Publication of JP7278595B2 publication Critical patent/JP7278595B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019551363A 2017-03-16 2018-03-16 Ｃｄ３２１マーカーの発現に基づく循環腫瘍細胞の検出、定量化、及び／又は単離 Active JP7278595B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161411.8 2017-03-16
EP17161411 2017-03-16
PCT/EP2018/056760 WO2018167312A1 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Publications (3)

Publication Number Publication Date
JP2020512549A JP2020512549A (ja) 2020-04-23
JP2020512549A5 JP2020512549A5 (https=) 2021-04-08
JP7278595B2 true JP7278595B2 (ja) 2023-05-22

Family

ID=58387669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019551363A Active JP7278595B2 (ja) 2017-03-16 2018-03-16 Ｃｄ３２１マーカーの発現に基づく循環腫瘍細胞の検出、定量化、及び／又は単離

Country Status (8)

Country Link
US (2) US12123877B2 (https=)
EP (2) EP4235179B1 (https=)
JP (1) JP7278595B2 (https=)
KR (1) KR102583603B1 (https=)
AU (1) AU2018235021B2 (https=)
CA (1) CA3054915A1 (https=)
IL (1) IL269315B2 (https=)
WO (1) WO2018167312A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019202788A1 (de) * 2019-03-01 2020-09-03 Robert Bosch Gmbh Verfahren zum Zählen von Zelltypen oder Zellmarkern in einer Probe, insbesondere in einer Blutprobe
JP2020144054A (ja) * 2019-03-07 2020-09-10 学校法人昭和大学 末梢血循環癌細胞の検出方法及び検出装置
KR102654518B1 (ko) * 2020-05-26 2024-04-04 가톨릭대학교 산학협력단 Lsp1 결핍 t 세포
CN113009135B (zh) * 2021-02-19 2024-04-02 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用
CA3233047A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526761A (ja) 2003-10-31 2007-09-20 ヴィタテックス， インコーポレイテッド 循環性の腫瘍細胞および内皮細胞の検出のための血液試験のプロトタイプおよび方法
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
US20110059475A1 (en) 2008-05-09 2011-03-10 The University Of Nottingham Stabilisation of blood cell conjugates
WO2015095527A1 (en) 2013-12-20 2015-06-25 The General Hosptial Corporation Methods and assays relating to circulating tumor cells
WO2016118086A1 (en) 2015-01-21 2016-07-28 Agency For Science, Technology And Research Column-based device and method for retrieval of rare cells based on size, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
WO2006130737A1 (en) * 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
CA2628390A1 (en) * 2005-11-02 2007-05-18 The Regents Of The University Of Michigan Molecular profiling of cancer
CA2572530A1 (en) * 2005-12-30 2007-06-30 Centocor, Inc. A method for determining the phenotype of cells
EP2199798A1 (en) * 2008-12-18 2010-06-23 Universite Libre De Bruxelles Diagnostic method and kit of circulating tumor cells
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
CN105102978B (zh) * 2013-02-02 2018-11-02 杜克大学 分离循环肿瘤细胞的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526761A (ja) 2003-10-31 2007-09-20 ヴィタテックス， インコーポレイテッド 循環性の腫瘍細胞および内皮細胞の検出のための血液試験のプロトタイプおよび方法
US20110059475A1 (en) 2008-05-09 2011-03-10 The University Of Nottingham Stabilisation of blood cell conjugates
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
WO2015095527A1 (en) 2013-12-20 2015-06-25 The General Hosptial Corporation Methods and assays relating to circulating tumor cells
JP2017503488A (ja) 2013-12-20 2017-02-02 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ
WO2016118086A1 (en) 2015-01-21 2016-07-28 Agency For Science, Technology And Research Column-based device and method for retrieval of rare cells based on size, and uses thereof

Also Published As

Publication number Publication date
EP3596467A1 (en) 2020-01-22
IL269315A (en) 2019-11-28
EP4235179C0 (en) 2025-08-13
EP4235179A3 (en) 2023-11-15
JP2020512549A (ja) 2020-04-23
WO2018167312A1 (en) 2018-09-20
AU2018235021B2 (en) 2024-07-11
EP3596467B1 (en) 2023-09-27
AU2018235021A1 (en) 2019-09-12
EP3596467C0 (en) 2023-09-27
IL269315B1 (en) 2025-01-01
US20210190787A1 (en) 2021-06-24
IL269315B2 (en) 2025-05-01
KR20190142330A (ko) 2019-12-26
EP4235179A2 (en) 2023-08-30
US20250027946A1 (en) 2025-01-23
US12123877B2 (en) 2024-10-22
CA3054915A1 (en) 2018-09-20
EP4235179B1 (en) 2025-08-13
KR102583603B1 (ko) 2023-10-05

Similar Documents

Publication Publication Date Title
US20250027946A1 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
JP6557827B2 (ja) 癌治療用医薬組成物
JP2021527082A (ja) 新規な免疫チェックポイント阻害剤
JP2018102299A (ja) 膀胱癌の処置および診断のための方法および組成物
CN106999576B (zh) 癌细胞特异性抗体、抗癌剂、及癌症的检查方法
JP2008546387A (ja) 癌を処置および診断するための組成物および方法
CN104823054A (zh) 对修饰后自体表位的抗肿瘤免疫应答
CN110945030A (zh) 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
KR20180110133A (ko) 일차 위선암의 체세포 프로모터 랜드스케이프를 나타내는 후성유전학적 프로파일링
JP2019528437A (ja) 腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
JP5808288B2 (ja) 微小胞膜タンパク質及びその応用
Yang et al. Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues
WO2023107964A1 (en) Receptor-mediated delivery of nucleic acids
JP2022072531A (ja) 女性ホルモン依存性がんの悪性度及び予後の判定のためのバイオマーカー
US20240418722A1 (en) Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling
WO2024083790A1 (en) Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
JP2026511106A (ja) 抗クローディン－１抗体を使用したがん治療のためのバイオマーカー
CN120202412A (zh) 小细胞肺癌肿瘤抗原及其用途
Maio et al. High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients
Galluzzi et al. An immunosurveillance mechanism controls cancer cell ploidy. Supplementary Material.
WO2019018729A1 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
BR112018073414B1 (pt) Métodos in vitro para determinar o prognóstico de um indivíduo com um tumor sólido, e para monitorar a eficácia de um tratamento terapêutico de um tumor sólido, e, método para identificar uma molécula que atua como uma molécula antitumoral contra um tumor sólido

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230428

R150 Certificate of patent or registration of utility model

Ref document number: 7278595

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150